Our key innovations include: A disulfidptosis subtyping framework identifying Cluster B with enhanced immune infiltration; A Dis score model prognosticating PCa survival and immunotherapy response; Experimental validation of CCNB2 as a disulfidptosis regulator via dual-pathway activation. Here, CCNB2 is linked to posterior cortical atrophy.